Harbour Investments Inc. Purchases 4,251 Shares of Omeros Corporation $OMER

Harbour Investments Inc. raised its position in shares of Omeros Corporation (NASDAQ:OMER) by 46.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,469 shares of the biopharmaceutical company’s stock after acquiring an additional 4,251 shares during the quarter. Harbour Investments Inc.’s holdings in Omeros were worth $40,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Wealth Enhancement Advisory Services LLC bought a new stake in Omeros during the 1st quarter valued at approximately $579,000. Hsbc Holdings PLC bought a new stake in Omeros during the 1st quarter valued at approximately $142,000. Nuveen LLC bought a new stake in Omeros during the 1st quarter valued at approximately $938,000. Wellington Management Group LLP bought a new stake in Omeros during the 1st quarter valued at approximately $1,118,000. Finally, Invesco Ltd. boosted its position in Omeros by 169.1% during the 1st quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company’s stock valued at $716,000 after acquiring an additional 54,696 shares in the last quarter. 48.79% of the stock is owned by institutional investors.

Analysts Set New Price Targets

OMER has been the topic of several research reports. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price objective on shares of Omeros in a research report on Wednesday, October 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a report on Wednesday, October 8th. HC Wainwright lifted their target price on shares of Omeros from $9.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, October 15th. WBB Securities reiterated a “strong-buy” rating and set a $45.00 target price on shares of Omeros in a report on Wednesday, October 15th. Finally, Wall Street Zen upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.50.

Omeros Stock Performance

OMER stock opened at $7.55 on Friday. The firm has a 50 day moving average price of $4.93 and a 200-day moving average price of $4.58. Omeros Corporation has a 52-week low of $2.95 and a 52-week high of $13.60. The firm has a market capitalization of $513.85 million, a price-to-earnings ratio of -3.58 and a beta of 2.32.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.02. The firm had revenue of $28.60 million during the quarter, compared to analysts’ expectations of $0.31 million. As a group, sell-side analysts forecast that Omeros Corporation will post -3.09 earnings per share for the current fiscal year.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.